Loading clinical trials...

RECRUITINGPHASE1

Study of High Efficient Killing Cell Therapy for Advanced NSCLC

Phase I Study of High Efficient Killing Cell Therapy for Advanced Non Small Cell Lung Cancer

NCT03193567•Ruijin Hospital

Summary

The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer

Detailed Description

Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female patients' age from 18 years to 70 years.
•Patients who have a life expectancy of at least 3 months.
•pathologically confirmed non-small cell lung cancer.
•failed in previous standard chemotherapy and targeted therapy.
•Karnofsky performance status 0-1.
•adequate organ functions.

Exclusion Criteria

•Pregnant and lactating women.
•Patients with T cell lymphoma, syphilis, AIDS or combination
•Patients with highly allergic or have a history of severe allergies
•Patients with severe hepatic or renal dysfunction
•Patients with severe autoimmune disease or who is being treated with immunosuppressive agents
•Patients with severe infection not controlled or High fever
•Patients with organ transplantation or waiting for organ transplantation.
•Patients with brain metastasis
•Patients with severe coagulopathy (e.g. hemophilia)
•Patients without adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.

Locations (1)

Ruijin Hospital

Shanghai, China

Key Dates

Start Date

September 14, 2017

Primary Completion Date

May 1, 2025

Completion Date

May 1, 2025

Last Updated

November 19, 2024

Enrollment

ESTIMATED participants

Conditions

Non Small Cell Lung Cancer

Interventions

HEKT cell

BIOLOGICAL

Contacts

Lei H Du, M.S

CONTACT

13918570392 sealing821201@hotmail.com

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of High Efficient Killing Cell Therapy for Advanced NSCLC

Inclusion Criteria

Exclusion Criteria

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)